New opportunities in oncology with sustained drug delivery

Long-acting drug delivery therapies have enormous potential to improve the lives of cancer patients. One of the greatest challenges faced by our pharmaceutical partners lies in creating formulations that are compatible with the variety of powerful Active Pharmaceutical Ingredients (APIs) used in oncology therapies. But it’s a challenge that our team is helping our partners overcome with our medical grade biomaterials and expertise.

We work with partners worldwide across the continuum of healthcare to create unique drug delivery solutions in oncology that bring progress to life for patients

15+

Years

15+ years of experience in sustained drug delivery applications.

30+

Years

30+ years of experience working with the world’s leading pharmaceutical companies.

150+

Years

150+ years of combined scientific discovery and heritage as part of dsm-firmenich.

Creating next-generation therapies with TheraPEA™

Our TheraPEA™ polyester amide platform is unlocking entirely new therapeutic opportunities for the pharmaceutical industry through its ability to achieve multi-month, controlled drug release.

This highly tunable biomaterial has a zero-order degradation profile and good correlation in-vitro and in-vivo up to 180 days. Furthermore, the unique chemistry of TheraPEA™ changes the game even further through its compatibility with a wide range of challenging Active Pharmaceutical Ingredients.

By developing customized drug delivery solutions with our partners in this way, we can enable longer duration therapies for patients with the potential to increase therapy adherence – and allow for improved clinical outcomes, better healthcare economics and significantly less medical waste.

Learn more about our drug delivery solutions.

Discover our drug delivery solutions for oncology

Both our implantable and injectable TheraPEA™ forms enable the sustained release of APIs for longer duration oncological therapies. Because our solution is compatible with both nucleophilic small molecules and biologic drugs, this unlocks the potential for less frequent dosing for cancer patients with a more controlled disease state, plus greater access to treatments.

Beyond our TheraPEA™ platform, we also draw on our portfolio of natural biomaterials to provide a functional, biocompatible scaffold for sustained release drug delivery that is proven to be safe and effective in humans.